Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy. Clinical Trials Registration.ȃGerman Registry for Clinical Trials (DRKS00025254).
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e510-e513 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lehrnbecher, Thomas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 11.02.2023 Date Revised 20.02.2023 published: Print ErratumIn: Clin Infect Dis. 2023 Jan 06;:. - PMID 36617214 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac570 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344209326 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344209326 | ||
| 003 | DE-627 | ||
| 005 | 20231226022231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac570 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344209326 | ||
| 035 | |a (NLM)35901198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lehrnbecher, Thomas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2023 | ||
| 500 | |a Date Revised 20.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Clin Infect Dis. 2023 Jan 06;:. - PMID 36617214 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy. Clinical Trials Registration.ȃGerman Registry for Clinical Trials (DRKS00025254) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a child | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Sack, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Speckmann, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Groll, Andreas H |e verfasserin |4 aut | |
| 700 | 1 | |a Boldt, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Siebald, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Hettmer, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Demmerath, Eva-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Reemtsma, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Schenk, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Ciesek, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Klusmann, Jan-Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Jassoy, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Hoehl, Sebastian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e510-e513 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e510-e513 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac570 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e510-e513 | ||